Milestone Pharmaceuticals Inc. Common Shares (MIST)

FairStock Score: 17/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham investor, I look first for a durable business with consistent earning power. Milestone is not that yet. In the fiscal Q2 2026 quarter ended 2026-06-30, it reported revenue of $559,000 and a net loss of $28.6 million. In fiscal Q1 2026, revenue was $238,000 against a $26.1 million loss. Full-year losses were $63.1 million in FY2025, $41.5 million in FY2024, and $59.7 million in FY2023. The company has CARDAMYST (etripamil) nasal spray for acute PSVT and is developing it for AFib-RVR, but tiny revenue against large losses shows commercialization is not yet covering the cost structure. A moat would require physician adoption, payer coverage, and clinical differentiation; the figures provided do not demonstrate pricing power or recurring profits. Financial health is weak. Trailing free cash flow is negative $61.6 million, a FairStock calculation, and the FCF yield of -64.6% on a $95.4 million market cap means the company burns cash rapidly relative to its value. The debt-to-equity ratio is 7.79, the Altman Z-Score is -2.81, and the Piotroski F-Score is 3/9, all FairStock calculations. At the 2026-10-13 close of $0.77, the P/B is 5.89 while book value is likely small and shrinking with losses. The P/E is meaningless at -1.18 because there are no profits. Growth is optionality, not a proven trajectory. If etripamil gains adoption and AFib-RVR succeeds, revenue could scale. But Graham would demand a margin of safety; here, the safety comes only from the option value of the pipeline, not from current earnings or assets.

In plain English: Milestone Pharmaceuticals is a small biotech developing CARDAMYST, an etripamil nasal spray for a rapid heart rhythm condition called PSVT, and also studying it for another irregular heartbeat condition called AFib-RVR. The business looks weak: it earns very little revenue and loses tens of millions of dollars, while burning significant cash. The share price is low, but because there are no profits to value, it looks speculative rather than clearly cheap or expensive.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer